FDA Approved: BIVALIRUDIN — Supplemental Application (Civica, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BIVALIRUDIN from Civica, Inc., resulting in an approved update to the NDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Heparin-induced Thrombocytopenia

Drugs mentioned

• Bivalirudin (bivalirudin)

Snippet

SUPPL AP for BIVALIRUDIN (BIVALIRUDIN)